查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1990348

生物可降解支架市场：按产品类型、材料、应用和最终用户分類的全球市场预测 – 2026-2032 年

Biodegradable Stents Market by Product Type, Material, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，可生物降解支架市场价值将达到 4.4859 亿美元，到 2026 年将成长至 4.6924 亿美元，复合年增长率为 5.19%，到 2032 年将达到 6.3932 亿美元。

主要市场统计数据
基准年 2025 4.4859亿美元
预计年份：2026年 4.6924亿美元
预测年份：2032年 6.3932亿美元
复合年增长率 (%) 5.19%

这是一本权威的生物可降解支架入门指南。内容涵盖临床进展、材料方面的重大进步、法规环境以及策略部署趋势。

生物可降解支架透过提供临时机械支撑，最大限度地减少异物长期滞留，正在为介入性心臟病学和血管内治疗带来模式转移。这项技术的发展历程已从早期临床应用难度较高的聚合物支架，演变为现今注重材料科学、可控吸收动力学和递送方式的多样化平台方案。如今，临床医生、器械工程师和医院采购团队在评估这些产品时，不仅关注支架的短期性能，还关注中长期血管治疗效果、影像学相容性以及对再次介入治疗的影响。

材料科学、成像技术和混合商业化模式的进步如何推动下一波可生物降解支架的临床应用和技术差异化？

生物可降解支架领域正经历变革性的转变，重塑临床预期、生产重点和商业化策略。从第一代生物可吸收血管支架中汲取的早期经验促使临床实验室设计、植入尺寸确定和影像学追踪采取更严谨的方法，从而推动研发人员改善支架梁形态、径向强度和吸收时间。这些技术改进，以及辅助成像技术（光学同调断层扫描和高解析度血管内成像）的进步，使得对支架与组织整合情况和血管治疗状态进行详细评估成为可能，这有助于监管申报和增强临床医生的信心。

评估 2025 年的累积关税措施如何重塑可生物降解支架领域的采购经济、製造地和临床部署时间表。

2025年实施或扩大的累积关税措施对可生物降解支架生态系相关相关人员的采购经济、供应链建构和采购决策产生了实质影响。对某些原材料和成品医疗设备征收的关税推高了依赖跨境供应关键原材料（例如高纯度镁合金和特殊聚合物）的製造商的最终成本，同时也提高了医院采购委员会的价格敏感度。为应对这项挑战，製造商正在加快双源采购策略的实施，实现生产基地的地域多角化，并明确长期供应商合同，以降低贸易政策进一步波动带来的风险。

详细的細項分析揭示了影响可生物降解支架技术采用的临床定位、材料权衡和市场差异化因素。

细分市场分析揭示了清晰的临床、技术和商业性趋势，这些趋势指导着产品、材料、应用、终端用户和分销等各个维度的策略优先排序。依产品类型划分，竞争产品线分为可生物降解聚合物涂层金属支架和可生物吸收血管支架，后者进一步细分为球囊扩张式和自扩张式装置。这些指南至关重要，因为输送性能、径向支撑力和展开精确度会影响临床医生的选择和手术流程。依材料划分，平台主要集中在镁合金或聚左旋乳酸(PLA) 基材上，而聚左旋乳酸的各种变体，例如复合 PLA 和 PLLA，会改变降解特性和成像特征，从而影响追踪通讯协定和患者选择。

透过区域比较分析，揭示美洲、欧洲、中东和非洲以及亚太地区在监管差异、临床引入模式和生产因素方面的细微差别。

生物可降解支架的区域表现和策略重点在美洲、欧洲、中东和非洲以及亚太地区存在显着差异，这主要受法律规范、临床实践和生产能力的影响。美洲拥有先进的心臟导管介入网络和集中的高发心臟中心，是展示具有明显手术优势且与现有影像工作流程相容的器械的理想示范区。支付方的考虑和医院的采购週期指南部署策略和循证方案的製定。在欧洲、中东和非洲，由于监管环境的碎片化和报销计画的多样性，部署率各不相同。先进心臟中心的早期应用案例与需要更广泛的卫生经济学验证才能说服支付方的市场并存。

公司层面的策略分析，重点在于可生物降解支架领域的创新路径、伙伴关係模式和商业性竞争，进而推动竞争优势。

生物降解支架领域的企业发展趋势呈现出多元化的特点，既有成熟的循环系统製造商，也有专注于医疗技术创新的企业，还有整合了材料科学和监管专业知识的垂直整合供应商。主要企业持续投资于基于临床医生回馈的迭代产品开发、采用可靠影像学终点的受控临床试验以及旨在改善长期血管护理的上市后调查计画。材料供应商与医疗设备製造商 (OEM) 之间的策略合作日益普遍，从而能够快速改进合金成分、聚合物混合物和涂层化学，以优化吸收时间和机械性能。

为了加快企业采用可生物降解支架、确保供应链安全以及使临床证据与商业策略保持一致，我们提出了可操作的跨部门建议。

产业领导者应协调临床、生产和商业策略，以加速安全部署并降低营运风险。优先投资于严谨的临床证据项目，利用高解析度成像和真实世界临床註册数据，在明确定义的患者群体中验证支架的生物相容性、长期管腔行为和对比疗效。这些数据有助于增强临床医生的信心，并支持差异化品牌建立。同时，透过多元化镁合金和特殊聚合物的原材料来源、探索本地组装方案以及建立战略库存缓衝，降低供应链风险，以应对贸易政策波动和零件短缺。

为了支持我们的策略见解，我们采用了一种透明的多模态调查方法，结合了临床证据、监管审查、专家访谈和供应链分析。

本研究采用多模态调查方法，整合了同行评审的临床文献、监管指导文件、医疗设备标籤检视以及对临床医生、供应链专家和行业高管的访谈，以得出平衡且基于证据的结论。在整合临床证据时，优先考虑随机对照试验和以影像学终点为指标的前瞻性观察性研究，同时纳入专家问捲和结构化访谈作为补充分析，以了解从业人员的经验、应用障碍和培训需求。监管审查考虑了区域核准流程和上市后监测要求，尤其关注与可吸收材料和支架相关终点相关的器材特定要求。

为了负责任地扩大可生物降解支架的使用，需要总结技术成熟度、临床实施路径和策略重点。

生物可降解支架正处于一个转折点，材料的进步、实用混合设计的出现以及更严格的临床评估，预计将生物可降解技术的未来潜力转化为可靠的临床应用。该领域已从前几代产品的挑战中吸取经验，并开发出能够更好地平衡急性期机械性能要求与可控降解、亲和性以及更精密的植入系统的新技术。儘管不同临床环境和地区的应用情况可能有所不同，但器械性能、临床医生培训和监管规定的累积完善，为生物可降解支架更广泛地应用于心臟和外周介入治疗提供了切实可行的途径。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 生物可分解支架市场：依产品类型划分

  • 可生物降解聚合物涂层金属支架
  • 生物可吸收血管支架
    • 气球膨胀类型
    • 自膨胀型

第九章：可生物降解支架市场：依材料分类

  • 镁合金
  • 聚左旋乳酸（PLLA）
    • 复合PLA
    • PLLA

第十章：可生物降解支架市场：依应用领域划分

  • 冠状动脉疾病
    • 急性心肌梗塞
    • 慢性完全闭塞
  • 周边动脉疾病

第十一章 生物可降解支架市场：依最终用户划分

  • 门诊手术中心
  • 医院
    • 心臟中心
    • 循环系统

第十二章 可生物降解支架市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 生物可降解支架市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 可生物降解支架市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国可生物降解支架市场

第十六章：中国可生物降解支架市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Alvimedica
  • Amaranth Medical Inc.
  • Arterius Limited
  • BIoTronik SE & Co. KG
  • Boston Scientific Corporation
  • Cardionovum GmbH
  • Elixir Medical Corporation
  • Kyoto Medical Planning Co. Ltd.
  • Lepu Medical Technology Co. Ltd.
  • Medtronic PLC
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • OrbusNeich Medical Company Limited
  • REVA Medical LLC
  • S3V Vascular Technologies
  • Terumo Corporation
  • Xenogenics Corporation
Product Code: MRR-4D00F1312C7E

The Biodegradable Stents Market was valued at USD 448.59 million in 2025 and is projected to grow to USD 469.24 million in 2026, with a CAGR of 5.19%, reaching USD 639.32 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 448.59 million
Estimated Year [2026] USD 469.24 million
Forecast Year [2032] USD 639.32 million
CAGR (%) 5.19%

An authoritative introduction to biodegradable stents that frames clinical evolution, material breakthroughs, regulatory context, and strategic adoption dynamics

Biodegradable stents represent a paradigm shift in interventional cardiology and endovascular therapy, driven by the pursuit of transient mechanical support that minimizes long-term foreign-body presence. The technology arc has moved from early polymer-based scaffolds with high-profile clinical setbacks toward a diversified set of platform approaches that emphasize material science, controlled resorption kinetics, and deliverability. Clinicians, device engineers, and hospital procurement teams now evaluate these products not only on acute scaffold performance but on mid- and long-term vessel healing, imaging compatibility, and implications for repeat interventions.

Simultaneously, regulatory pathways and post-market surveillance frameworks have matured to incorporate device-specific endpoints such as late lumen loss, scaffold thrombosis, and vessel remodeling. This evolution has encouraged iterative improvements in magnesium alloy formulations and refinements to poly-L-lactic acid constructs, while also stimulating innovations around polymer coatings for metallic stents that aim to combine the immediate mechanical reliability of metal with a bioresorbable interface. As adoption considerations become more nuanced, strategic questions center on clinical positioning, comparative evidence generation, and supply chain resilience, all of which will determine how biodegradable platforms integrate into standard care algorithms.

How material science, imaging advances, and hybrid commercialization models are driving the next wave of clinical adoption and technology differentiation in biodegradable stents

The landscape for biodegradable stents has experienced transformative shifts that are reshaping clinical expectations, manufacturing priorities, and commercialization strategies. Early lessons from first-generation bioresorbable vascular scaffolds catalyzed a more disciplined approach to trial design, implant sizing, and imaging-driven follow-up, prompting developers to iterate on strut geometry, scaffold radial strength, and resorption timelines. These technical refinements are accompanied by advances in adjunctive imaging-optical coherence tomography and high-resolution intravascular imaging-that enable granular assessment of scaffold integration and vessel healing, thereby informing both regulatory submissions and clinician confidence.

Concurrently, materials innovation has broadened the available toolkit: magnesium alloy platforms emphasize more rapid, controlled resorption with favorable mechanical profiles, while poly-L-lactic acid-based solutions focus on prolonged structural support with tunable degradation. The lines between permanent metal stents and bioresorbable concepts are blurring through hybrid approaches such as biodegradable polymer coatings on metallic scaffolds, which seek to balance long-term patency with reduced chronic inflammation. Market participants are also recalibrating commercial models, with suppliers prioritizing robust clinical evidence, tailored training programs for operators, and service-oriented post-market follow-up to accelerate adoption within centers of excellence and cardiology networks.

Assessment of how 2025 cumulative tariff actions have reshaped procurement economics, manufacturing footprints, and clinical adoption timelines in the biodegradable stent sector

Cumulative tariff measures enacted or expanded in 2025 exert a tangible influence on procurement economics, supply-chain structuring, and sourcing decisions for stakeholders in the biodegradable stent ecosystem. Tariffs on specific inputs and finished medical devices raise landed costs for manufacturers that rely on cross-border supply of critical raw materials such as high-purity magnesium alloy feedstock and specialty polymers, while also increasing the price sensitivity of hospital purchasing committees. In response, manufacturers have accelerated dual-sourcing strategies, regionalized production footprints, and clarified long-term supplier agreements to mitigate exposure to further trade policy volatility.

The tariff environment has also prompted a chain reaction that affects clinical adoption timing: health systems under cost pressure may delay elective procedures or prioritize devices with clearer near-term budgetary benefits, which in turn influences the cadence of evidence generation and real-world data collection. Some firms have adopted localized assembly and final testing to reduce tariff burdens on finished goods, thereby shifting capital investment and talent requirements toward regions with favorable trade treatments. Looking ahead, the cumulative effect of tariffs is better characterized as a driver of operational adaptation-reshaping pricing strategies, inventory policies, and partnership models-rather than a deterministic barrier to technological advancement.

In-depth segmentation insights that illuminate clinical positioning, material trade-offs, and go-to-market differentiators shaping adoption of biodegradable stent technologies

Segmentation analysis reveals distinct clinical, technical, and commercial dynamics across product, material, application, end-user, and distribution dimensions that guide strategic prioritization. Based on Product Type, the competitive set spans Biodegradable Polymer Coated Metallic Stents and Bioresorbable Vascular Scaffolds, with the latter further differentiated into Balloon Expandable and Self Expanding devices; these distinctions matter because deliverability, radial strength, and deployment precision influence operator preference and procedural workflows. Based on Material, platforms gravitate toward Magnesium Alloy or Poly-L-Lactic Acid substrates, where Poly-L-Lactic Acid variations such as Composite PLA and PLLA alter degradation profiles and imaging signatures, affecting follow-up protocols and patient selection.

Based on Application, clinical targeting bifurcates between Coronary Artery Disease and Peripheral Artery Disease, with Coronary Artery Disease use later stratified into Acute Myocardial Infarction and Chronic Total Occlusion contexts that present different lesion morphologies and risk tolerances. Based on End User, adoption pathways differ between Ambulatory Surgery Centers and Hospitals, and within hospitals the dynamics vary between Cardiac Centers and Cardiology Departments because high-volume, specialized cardiac centers often accelerate procedural innovations. Finally, based on Distribution Channel, commercial approaches split across Direct Sales and Distributors, and direct-sales models that deploy In House Sales Teams or Original Equipment Manufacturer partnerships change customer engagement intensity and post-sale service expectations. Understanding these segmentation layers clarifies where clinical evidence, training, and supply continuity will most effectively translate into adoption and commercial success.

Comparative regional intelligence that decodes regulatory nuances, clinical adoption patterns, and manufacturing influences across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional performance and strategic priorities for biodegradable stents differ markedly across the Americas, Europe, Middle East & Africa, and Asia-Pacific, driven by regulatory frameworks, clinical practices, and manufacturing capacity. In the Americas, advanced interventional cardiology networks and a concentrated set of high-volume cardiac centers make the region a proving ground for devices that demonstrate clear procedural advantages and compatibility with existing imaging workflows; payer considerations and hospital procurement cycles inform rollout strategies and evidence generation plans. In Europe, Middle East & Africa, fragmented regulatory landscapes and varied reimbursement policies create a mosaic of adoption speeds, where early adopters in advanced cardiac centers coexist with markets that require more extensive health-economic demonstration to convince payers.

The Asia-Pacific region combines rapidly expanding procedural volumes with strong manufacturing ecosystems and an increasing appetite for locally produced solutions. Local clinical investigators and regional regulators are playing a more visible role in shaping device design and post-market evidence requirements. Across all regions, differences in operator training pathways, hospital procurement practices, and supply chain resiliency underscore the need for nuanced regional commercialization roadmaps that align clinical data campaigns with local regulatory expectations and distribution capabilities. Harmonizing global clinical evidence strategies with region-specific value propositions will be decisive for organizations seeking multi-regional scale.

Strategic company-level analysis that highlights innovation pathways, partnership models, and commercial competencies driving competitive advantage in biodegradable stents

Company-level dynamics in the biodegradable stent domain are characterized by a mix of incumbent cardiovascular device manufacturers, specialized medtech innovators, and vertically integrated suppliers that combine materials science with regulatory expertise. Leading organizations consistently invest in iterative product development informed by operator feedback, controlled clinical studies with robust imaging endpoints, and post-market surveillance programs that address long-term vessel healing. Strategic partnerships between material suppliers and device OEMs are increasingly common, enabling faster optimization of alloy compositions, polymer blends, and coating chemistries that refine resorption timing and mechanical performance.

Smaller, more agile entrants focus on niche indications or platform enhancements-such as lower-profile delivery systems, hybrid scaffolds, or adjunctive imaging software-targeting centers of excellence where adoption velocity is highest. Across the competitive landscape, successful companies exhibit disciplined regulatory strategies, clear training and proctoring pathways for clinicians, and pragmatic pricing models that consider hospital capital constraints and procedural reimbursement realities. As supply-chain pressures and tariff-related cost dynamics continue to influence unit economics, firms with diversified manufacturing footprints and flexible distribution agreements will maintain tactical advantages in sustaining commercial momentum.

Actionable, cross-functional recommendations for companies to accelerate adoption, secure supply chains, and align clinical evidence with commercial strategies in biodegradable stents

Industry leaders should align clinical, manufacturing, and commercial strategies to accelerate safe adoption while mitigating operational risk. Prioritize investment in rigorous clinical evidence programs that leverage high-resolution imaging and real-world registries to demonstrate scaffold integration, late lumen behavior, and comparative outcomes in clearly defined patient cohorts; such data builds clinician trust and supports differentiated labeling. Concurrently, de-risk supply chains by diversifying raw-material sources for magnesium alloys and specialty polymers, exploring localized assembly options, and instituting strategic inventory buffers to guard against trade-policy disruptions or component shortages.

Commercially, tailor engagement models to end-user profiles: provide hands-on training and proctoring for cardiac centers that drive early adoption while offering simplified procurement pathways and technical support for ambulatory surgery centers. Emphasize hybrid product families-biodegradable polymer coatings on metallic platforms or hybrid scaffolds-that address the clinical demand for predictable acute performance with reduced long-term device footprint. Finally, adopt value-based pricing discussions with payers by correlating device attributes with procedural efficiency, reduced long-term complications, and potential downstream cost offsets, thereby aligning reimbursement conversations with clinical and economic evidence.

A transparent, multi-modal research methodology combining clinical evidence synthesis, regulatory review, expert interviews, and supply-chain analysis to underpin strategic insights

The research employed a multi-modal methodology that integrates peer-reviewed clinical literature, regulatory guidance documents, device labeling, and interviews with clinicians, supply-chain specialists, and industry executives to ensure balanced, evidence-driven conclusions. Clinical evidence synthesis prioritized randomized and prospective observational studies with imaging-based endpoints, while complementary analyses incorporated expert surveys and structured interviews to capture operator experience, adoption barriers, and training needs. Regulatory review considered regional pathways and post-market surveillance expectations, with attention to device-specific requirements for resorbable materials and scaffold-related endpoints.

Supply-chain and tariff analyses combined customs and trade policy reviews with interviews of procurement managers and component suppliers to map exposure to input-cost volatility and logistical constraints. Commercial modeling focused on segmentation-driven adoption scenarios without projecting aggregate market sizes, using case-study approaches to illustrate how product design, distribution strategy, and regional regulatory alignment influence commercial outcomes. Throughout, methodological triangulation-cross-verifying insights from clinical, regulatory, and commercial sources-was used to increase the robustness of findings and to highlight areas where targeted primary research would most effectively close evidence gaps.

A concise conclusion that synthesizes technology readiness, clinical adoption pathways, and strategic priorities for responsible expansion of biodegradable stent use

Biodegradable stents now stand at an inflection point where material advances, pragmatic hybrid designs, and more rigorous clinical evaluation can translate the promise of resorbable technology into durable clinical use. The field has learned from early generational challenges and has responded with technologies that better balance acute mechanical needs with controlled degradation, enhanced imaging compatibility, and refined deployment systems. Adoption will be uneven across clinical contexts and geographies, but the cumulative progress in device performance, clinician training, and regulatory clarity provides a realistic pathway for broader integration into interventional cardiology and peripheral interventions.

Successful stakeholders will be those who combine strong clinical evidence strategies with resilient manufacturing and distribution approaches, mindful of trade-policy and reimbursement dynamics. By focusing on clear clinical differentiation, localized commercial execution, and systematic post-market learnings, the industry can responsibly expand device availability while preserving patient safety and procedural effectiveness. The trajectory for biodegradable stents is not a simple replacement of permanent implants but a more nuanced expansion of therapeutic options that can be tailored to patient risk profiles and lesion characteristics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biodegradable Stents Market, by Product Type

  • 8.1. Biodegradable Polymer Coated Metallic Stents
  • 8.2. Bioresorbable Vascular Scaffolds
    • 8.2.1. Balloon Expandable
    • 8.2.2. Self Expanding

9. Biodegradable Stents Market, by Material

  • 9.1. Magnesium Alloy
  • 9.2. Poly-L-Lactic Acid
    • 9.2.1. Composite Pla
    • 9.2.2. Plla

10. Biodegradable Stents Market, by Application

  • 10.1. Coronary Artery Disease
    • 10.1.1. Acute Myocardial Infarction
    • 10.1.2. Chronic Total Occlusion
  • 10.2. Peripheral Artery Disease

11. Biodegradable Stents Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Hospitals
    • 11.2.1. Cardiac Centers
    • 11.2.2. Cardiology Departments

12. Biodegradable Stents Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Biodegradable Stents Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Biodegradable Stents Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Biodegradable Stents Market

16. China Biodegradable Stents Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Alvimedica
  • 17.7. Amaranth Medical Inc.
  • 17.8. Arterius Limited
  • 17.9. Biotronik SE & Co. KG
  • 17.10. Boston Scientific Corporation
  • 17.11. Cardionovum GmbH
  • 17.12. Elixir Medical Corporation
  • 17.13. Kyoto Medical Planning Co. Ltd.
  • 17.14. Lepu Medical Technology Co. Ltd.
  • 17.15. Medtronic PLC
  • 17.16. Meril Life Sciences Pvt. Ltd.
  • 17.17. MicroPort Scientific Corporation
  • 17.18. OrbusNeich Medical Company Limited
  • 17.19. REVA Medical LLC
  • 17.20. S3V Vascular Technologies
  • 17.21. Terumo Corporation
  • 17.22. Xenogenics Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIODEGRADABLE STENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIODEGRADABLE STENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BIODEGRADABLE STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BIODEGRADABLE STENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY BIODEGRADABLE POLYMER COATED METALLIC STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY BIODEGRADABLE POLYMER COATED METALLIC STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY BIODEGRADABLE POLYMER COATED METALLIC STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY BALLOON EXPANDABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY BALLOON EXPANDABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY BALLOON EXPANDABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY SELF EXPANDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY SELF EXPANDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY SELF EXPANDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY MAGNESIUM ALLOY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY MAGNESIUM ALLOY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY MAGNESIUM ALLOY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY COMPOSITE PLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY COMPOSITE PLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY COMPOSITE PLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY PLLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY PLLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY PLLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CHRONIC TOTAL OCCLUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CHRONIC TOTAL OCCLUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CHRONIC TOTAL OCCLUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CARDIOLOGY DEPARTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CARDIOLOGY DEPARTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CARDIOLOGY DEPARTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS BIODEGRADABLE STENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 141. GCC BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GCC BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 144. GCC BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 145. GCC BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 146. GCC BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. GCC BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GCC BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 168. G7 BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. G7 BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. G7 BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 171. G7 BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 172. G7 BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 173. G7 BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. G7 BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. G7 BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 177. NATO BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. NATO BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. NATO BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 180. NATO BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 181. NATO BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 182. NATO BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. NATO BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 184. NATO BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. NATO BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES BIODEGRADABLE STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA BIODEGRADABLE STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)